Looking for efficiency rather than efficacy in randomized controlled trials in oncology

Annals of Oncology

Volumn 21, Issue 7, 2010, Pages 1391-1393

  Floriani, I ^a   Garattini, S ^a   Torri, V ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUOROURACIL; GEMCITABINE; IRINOTECAN; K RAS PROTEIN; PACLITAXEL; PLACEBO; SORAFENIB;

BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RESEARCH; CANCER SURVIVAL; CANCER THERAPY; CLINICAL PRACTICE; CLINICAL STUDY; COLORECTAL CANCER; DIARRHEA; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG ERUPTION; EDITORIAL; EVENT FREE SURVIVAL; HUMAN; INFECTION; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; METASTASIS POTENTIAL; MUTATION; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PUBLICATION; RISK BENEFIT ANALYSIS; STOMATITIS; TREATMENT RESPONSE; CANCER PROGNOSIS; CANCER RISK; CLINICAL OUTCOME; HAZARD RATIO; HEALTH CARE QUALITY; MALIGNANT NEOPLASM; ONCOGENE K RAS; ONCOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); STUDY DESIGN; SURVIVAL RATE;

EID: 77954299416     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq266     Document Type: Editorial

References (20)

1. Vale C, Stewart L, Tierney J. Trends in UK cancer trials: results from the UK Coordinating Committee for Cancer Research National Register of Cancer Trials. Br J Cancer 2005; 92: 811-814.
2. Djulbegovic B, Kumar A, Soares HP et al. Treatment success in cancer. Arch Intern Med 2008; 168: 632-642.
3. Booth CM, Cescon DW, Wang L et al. Evolution of the randomized controlled trial in oncology over three decades. J Clin Oncol 2008; 26: 5458-5464.
4. Van Cutsem E, Kohne C, Hitre E, Zaluski L et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-1417.
5. Sandler A, Gray R, Perr MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-2550.
6. Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357: 2666-2676.
7. Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25: 1960-1966.
8. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-134.
9. Naylor CD, Chen E, Strauss B. Measured enthusiasm: does the method of reporting trial results alter perceptions of therapeutic effectiveness? Ann Intern Med 1992; 117: 916-921.
10. Bobbio M, Demicheli B, Giustetto G. Completeness of reporting trial results: effect on physicians' willingness to prescribe. Lancet 1994; 343: 1209-1211.
11. Chao C, Studts JL, Abell T et al. Adjuvant chemotherapy for breast cancer: how presentation of recurrence risk influences decision-making. J Clin Oncol 2003; 21: 4299-4305.
12. Lacy CR, Barone JA, Suh DC et al. Impact of presentation of research results on likelihood of prescribing medications to patients with left ventricular dysfunction. Am J Cardiol 2001; 87: 203-207.
13. Moher D, Hopewell S, Schulz KF et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 2010; 340: c869.
14. Nuovo J, Melnikow J, Chang D. Reporting number needed to treat and absolute risk reduction in randomized controlled trials. JAMA 2002; 287: 2813-2814.
15. Ajani JA. The area between the curves gets no respect: is it because of the median madness? J Clin Oncol 2008; 25: 5531.
16. Seruga B, Hertz PC, Wang L et al. Absolute benefits of medical therapies in phase III clinical trials for breast and colorectal cancer. Ann Oncol 2009 November 30 [Epub ahead of print]. doi: 10.1093/annonc/mdp552
17. Sobrero A, Bruzzi P. Incremental advance or seismic shift? The need to raise the bar of efficacy for drug approval. J Clin Oncol 2009; 27: 5868-5873.
18. Fojo T, Grady C. How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. J Natl Cancer Inst 2009; 101: 1044-1048.
19. De Palma R, Liberati A, Ciccone G et al. Developing clinical recommendations for breast, colorectal, and lung cancer adjuvant treatments using the GRADE system: a study from the Programma Ricerca e Innovazione Emilia Romagna Oncology Research Group. J Clin Oncol 2008; 26: 1033-1039.
20. Guyatt GH, Oxman AD, Vist G et al. for the GRADE Working Group. Rating quality of evidence and strength of recommendations GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336: 924-926.